Emerging issues in androgen replacement therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 1, 1997, Pages 3-8

  Bhasin, Shalender ^a   Bremner, William J ^b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; ANDROGEN;

CACHEXIA; DRUG ABSORPTION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; DRUG UPTAKE; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; MUSCLE DEVELOPMENT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; BLOOD; FEMALE; MALE; MENOPAUSE; PHYSIOLOGY; WASTING SYNDROME;

HUMAN IMMUNODEFICIENCY VIRUS;

ANDROGENS; DRUG MONITORING; FEMALE; HUMANS; MALE; MENOPAUSE; TESTOSTERONE; WASTING SYNDROME;

EID: 0030640841     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.1.3     Document Type: Review

References (28)

1. Bagatell CJ, Bremner WJ. 1996 Androgens in men - uses and abuses. N Engl J Med. 334:707-714.
2. Cunningham GR, Cordero E, Thornby JI. 1989 Testosterone replacement with transdermal therapeutic systems. JAMA. 261:2525-2530.
3. Meikle AW, Mazer NA, Moellmer JF, et al. 1992 Enhanced transdermal delivery of testosterone across the nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab. 74:623-628.
4. Sundaram K, Kumar N, Bardin CW. 1996 7-α-methyl-19-nortestosterone (MENT): an ideal androgen for replacement therapy. In: Bhasin S, Gabelnick H, Spieler JM, Swerdloff RS, Wang C (eds) Pharmacology, Biology, and Clinical Applications of Androgens. New York: Wiley-Liss; 493-497.
5. Bhasin S, Swerdloff RS, Steiner BS, et al. 1992 A biodegradable testosterone microsphere formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab 74:75-83.
6. Salehian B, Wang C, Alexander G, et al. 1995 Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate: a clinical research center study. J Clin Endocrinol Metab. 80:3567-3575.
7. Cummings DE, Bremner WJ. 1994 Prospects for new hormonal male contraceptives. In: Bremner WJ (ed) Clinical Andrology, Endocrinology and Metabolism Clinics of North America. Philadelphia: W.B. Saunders; 23:893-992.
8. World Health Organization Task Force on Methods for the Regulation of Male Fertility. 1990 Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336:955-959.
9. Tom L, Bhasin S, Salameh W, et al. 1992 Induction of azoospermia in normal men with combined Nal-Glu GnRH antagonist and testosterone enanthate. J Clin Endocrinol Metab. 75:476-483.
10. Bhasin S, Storer TW, Berman N, et al. 1996 The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 335:1-6.
11. Bhasin S, Storer TW, Berman N, et al. Replacement doses of testosterone increase fat-free mass, muscle size and strength in hypogonadal men. J Clin Endocrinol Metab. In press.
12. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. 1982 Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 37:425-430.
13. Snyder PJ, Lawrence DA. 1980 Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 51:1335-1339.
14. Gooren LJ. 1994 A ten-year safety study of the oral androgen testosterone undecanoate. J Androl. 15:212-215.
15. Handelsman DJ, Conway AJ, Boylan LM. 1990 Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab. 71:216-222.
16. Partsch CJ, Weinbauer GF, Fang R, Nieschlag E. 1995 Injectable testosterone undecanoate has more favorable pharmacokinetics and pharmacodynamics than testosterone enanthate. Eur J Endocrinol. 132:514-519.
17. Finkelstein JS, Klibanski A, Neer RM, et al. 1987 Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med. 106:354-361.
18. Behre HM, Bohmeyer J, Nieschlag E. 1994 Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinul (Oxf) 40:341-349.
19. Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren III, R, Murphy GP. 1995 Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol. 59:246-250.
20. Brown DC, Butler GE, Kelnar CJ, Wu FC. 1995 A double-blind, placebo-controlled study of the effects of low-dose testosterone undecanoate on the growth of small for age, prepubertal boys. Arch Dis Children. 73:131-135.
21. Wilson JD. Androgen abuse by athletes. Endocr Rev. 1988:9;181-99.
22. Mooradian AD, Morley JE, Korenman SG. 1987 Biological actions of androgens. Endocr Rev. 8:1-28.
23. Dobs AS, Dempsey MA, Landenson PW, Polk BF. 1488 Endocrine disorders in men infected with human immunodeficiency virus. Am J Med. 84:611-615.
24. Dluhy RG. 1990 The growing spectrum of HIV-related endocrine abnormalities. J Clin Endocrinol Metab. 70:563-565.
25. Tenover JS. 1992 1992 Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75:1092-1098.
26. Morley JE, Perry HM III, Kaiser FE, et al. 1993 Effects of testosterone replacement in old hypogonadal males: a preliminary study. J Am Geriatr Soc. 41:149-152.
27. Sherwin BB, Gelfand MM. 1984 Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in surgical menopause. Am J Obstet Gynecol. 148:552-557.
28. Sherwin BB. 1996 Androgen use in women. In: Bhasin S, Gabelnick H, Spieler JM, Swerdloff RS, Wang C (eds) Pharmacology, Biology, and Clinical Applications of Androgens. New York: Wiley-Liss; 319-324.